Together Pharma

Together Pharma ROE

The Return on Equity (ROE) of Together Pharma (TGTR.TA) as of Oct 8, 2026 is -3.52 %. In the previous year, Return on Equity (ROE) was 55.38 % — a change of -106.35% (lower).

ROE

-3.52 %

YoY

-106.35%

Last updated:

In 2024, Together Pharma's return on equity (ROE) was -3.52 %, a -106.35% increase from the 55.38 % ROE in the previous year.

The Together Pharma ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
3,163.32 ILS
Jan 1, 2018
503.69 ILS
Jan 1, 2019
140.62 ILS
Jan 1, 2020
86.28 ILS
Jan 1, 2021
-66.78 ILS
Jan 1, 2022
7,869.48 ILS
Jan 1, 2023
55.38 ILS
Jan 1, 2024
-3.52 ILS
The Together Pharma ROE history
YEARROEYoY
-3.52 %-106.35%
55.38 %-99.30%
7,869.48 %-11,883.66%
-66.78 %-177.40%
86.28 %-38.64%
140.62 %-72.08%
503.69 %-84.08%
3,163.32 %-1,294.51%
-264.82 %+704.63%
-32.91 %-104.38%
750.77 %—
Access this data via the Eulerpool API
Get Free API Key

Together Pharma Stock analysis

What does Together Pharma do? Together Pharma is one of the most popular companies on Eulerpool.

ROE Details

Decoding Together Pharma's Return on Equity (ROE)

Together Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Together Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Together Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Together Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Together Pharma stock

Return on Equity (ROE) of Together Pharma is -3.52 % in 2024.

Return on Equity (ROE) of Together Pharma changed from 55.38 % to -3.52 %, representing a -106.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Together Pharma since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Together Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Together Pharma

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Together Pharma